Portal de Periódicos da CAPES

p53 NUCLEAR ACCUMULATION IS NOT ASSOCIATED WITH DECREASED DISEASE-FREE SURVIVAL IN PATIENTS WITH NODE POSITIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER

2000; Lippincott Williams & Wilkins; Volume: 164; Issue: 4 Linguagem: Inglês

10.1016/s0022-5347(05)67136-4

1527-3792

Neil Fleshner, Linda Kapusta, DARREN EZER, Sender Herschorn, Laurence Klotz,

Urological Disorders and Treatments

No AccessJournal of UrologyOriginal Articles1 Oct 2000p53 NUCLEAR ACCUMULATION IS NOT ASSOCIATED WITH DECREASED DISEASE-FREE SURVIVAL IN PATIENTS WITH NODE POSITIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER NEIL FLESHNER, LINDA KAPUSTA, DARREN EZER, SENDER HERSCHORN, and LAURENCE KLOTZ NEIL FLESHNERNEIL FLESHNER More articles by this author , LINDA KAPUSTALINDA KAPUSTA More articles by this author , DARREN EZERDARREN EZER More articles by this author , SENDER HERSCHORNSENDER HERSCHORN More articles by this author , and LAURENCE KLOTZLAURENCE KLOTZ More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67136-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Although the majority of patients with node positive transitional cell carcinoma of the bladder have disease progression, a definitive subset is cured by surgery only. Nuclear accumulation of p53 has been associated with disease progression in patients with superficial transitional cell carcinoma and decreased survival in those with muscle invasive disease. We determined whether p53 status would predict survival in a cohort with nodal metastasis. Materials and Methods: We explored the comprehensive database of all 199 radical cystectomies performed at our institution between July 1988 and September 1999. The 59 patients in this database with node positive pathology comprise our study. We performed immunohistochemical analysis of specimens using the MAB1801 antibody with greater than 20% lymph node and primary tumor nucleus staining deemed positive. Additional covariates measured included patient age, sex, pathological disease stage, adjuvant chemotherapy and nodal stage. Disease-free survival curves were generated for the various covariates and compared using the log rank test. The Cox proportional hazards technique was used to determine covariate adjusted p53 survival. Results: In the cohort overall median disease-free survival was only 21 months, although 18% of patients were disease-free at 5 years. There was evidence of p53 nuclear accumulation in 54% of cases and complete agreement of nodal with bladder p53 nuclear accumulation. No significant baseline differences were noted in the covariates with respect to p53 nuclear accumulation. For stratum specific disease-free survival univariate and multivariate analyses revealed that only pathological stages p0-p2b versus p3-p4 (hazards ratio 2.86, p = 0.03), and nodal stages N2 versus N1 and N3 versus N1 (hazards ratio 3.84, p = 0.01 and hazards ratio 13.3, p = 0.0002, respectively) were significantly associated with prolonged disease-free survival, while p53 nuclear accumulation was not. Conclusions: Despite credible evidence for p53 nuclear accumulation prognostication in patients with in situ and invasive transitional cell carcinoma, this marker is not predictive of disease-free survival in node positive disease. References 1 : The impact of primary stage on survival in patients with lymph node positive bladder cancer. J Urol1999; 161: 72. Link, Google Scholar 2 : The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol1993; 149: 758. Link, Google Scholar 3 : Pelvic lymphadenectomy and radical cystectomy for transitional cell carcinoma of the bladder with pelvic nodal disease. Br J Urol1985; 57: 156. Google Scholar 4 : Results of radical cystectomy and pelvic lymphadenectomy for bladder cancer with pelvic node metastases. Urol Int1996; 57: 27. Google Scholar 5 : Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol1999; 161: 449. Link, Google Scholar 6 : Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J Urol1982; 128: 34. Link, Google Scholar 7 : NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology (Huntingt)1998; 12: 225. Google Scholar 8 : Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol1994; 152: 388. Link, Google Scholar 9 : Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med1994; 331: 1259. Google Scholar 10 : p53 and treatment of bladder cancer. Nature1997; 385: 123. Google Scholar 11 : Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol1993; 2: 4. Google Scholar 12 : Molecular alterations in bladder cancer. Cancer Surv1998; 32: 115. Google Scholar 13 : Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol1999; 162: 1496. Link, Google Scholar 14 : Discerning the function of p53 by examining its molecular interactions. Bioessays1993; 15: 703. Google Scholar 15 : MDM2 oncogene as a target for cancer therapy: an antisense approach. Int J Oncol1999; 15: 653. Google Scholar 16 : New concepts on the role of human papillomavirus in cell cycle regulation. Ann Med1999; 31: 175. Google Scholar 17 : Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res1993; 53: 4469. Google Scholar 18 : The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene1990; 5: 423. Google Scholar 19 : p53 Immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer1995; 71: 201. Google Scholar 20 : Nuclear overexpression of p53 in transitional cell carcinoma: a marker for disease progression. J Natl Cancer Inst1993; 85: 53. Google Scholar 21 : The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells. J Cancer Res Clin Oncol1999; 125: 357. Google Scholar From the Departments of Surgery (Urology) and Anatomic Pathology, Sunnybrook and Women’s College Health Sciences Center, University of Toronto, Toronto, Ontario, Canada© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byMori K, Mostafaei H, Enikeev D, Lysenko I, Quhal F, Kimura S, Karakiewicz P, Egawa S and Shariat S (2020) Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-AnalysisJournal of Urology, VOL. 204, NO. 1, (58-62), Online publication date: 1-Jul-2020.SMITH N, RUBENSTEIN J, EGGENER S and KOZLOWSKI J (2018) The p53 Tumor Suppressor Gene and Nuclear Protein: Basic Science Review and Relevance in the Management of Bladder CancerJournal of Urology, VOL. 169, NO. 4, (1219-1228), Online publication date: 1-Apr-2003. Volume 164Issue 4October 2000Page: 1177-1182 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordsforecastingcarcinoma, transitional cellbladdergenes, p53lymph nodesMetricsAuthor Information NEIL FLESHNER More articles by this author LINDA KAPUSTA More articles by this author DARREN EZER More articles by this author SENDER HERSCHORN More articles by this author LAURENCE KLOTZ More articles by this author Expand All Advertisement PDF downloadLoading ...